Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs
Sign Up to like & getrecommendations! Published in 2021 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.7075
Abstract: Key Points Question How commonly are drugs commercially available in the countries where they were tested? Findings This cross-sectional study found that 5 years after their approval in the US, 15% of novel drugs (5… read more here.
Keywords: drug trials; evaluation drug; high middle; trials high ... See more keywords
Abstract 4135791: Bleeding risk with non-vitamin K antagonist oral anticoagulants versus single antiplatelet therapy: A systematic review and meta-analysis of randomized controlled trials
Sign Up to like & getrecommendations! Published in 2024 at "Circulation"
DOI: 10.1161/circ.150.suppl_1.4135791
Abstract: Background: While non-vitamin K antagonist oral anticoagulants (NOACs) are more effective than single antiplatelets (mostly low-dose aspirin) at reducing stroke risk in patients with atrial fibrillation (AF), differences in bleeding risk between NOACs and single-dose… read more here.
Keywords: single antiplatelet; risk; events trials; trials high ... See more keywords
Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14020374
Abstract: Simple Summary Patients with medulloblastoma receive treatment according to a risk stratification, which is a combination of clinical and biological factors. To date there have been a limited number of trials for high-risk disease in… read more here.
Keywords: trials high; high risk; trial; risk medulloblastoma ... See more keywords